An Open-label, Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) in Combination with Propranolol and G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Multiple Myeloma Patients
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
An Open-label, Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) in Combination with Propranolol and G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Multiple Myeloma Patients. // Transplantation and Cellular Therapy. – URL: https://www.sciencedirect.com/science/article/pii/S2666636726008675?dgcid=rss_sd_all
An Open-label, Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) in Combination with Propranolol and G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Multiple Myeloma Patients. Transplantation and Cellular Therapy. https://www.sciencedirect.com/science/article/pii/S2666636726008675?dgcid=rss_sd_all
“An Open-label, Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) in Combination with Propranolol and G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Multiple Myeloma Patients.” Transplantation and Cellular Therapy.
@article{article70395,
title = {An Open-label, Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) in Combination with Propranolol and G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Multiple Myeloma Patients},
journal = {Transplantation and Cellular Therapy},
url = {https://www.sciencedirect.com/science/article/pii/S2666636726008675?dgcid=rss_sd_all}
}